Elevance Health, Inc. reported second-quarter 2026 results with total revenue of $50.47B, modestly above the prior-year quarter, while shareholders’ net income and diluted EPS declined to $1.46B and $6.71, respectively, compared with $1.74B and $7.72 a year earlier.
Financial Highlights
- Revenue was $50.47B, compared with $49.78B in the prior-year quarter; YoY change 1.4%.
- Net income was $1.46B, compared with $1.74B in the prior-year quarter; YoY change (16.1%).
- Diluted EPS was $6.71, compared with $7.72 in the prior-year quarter; YoY change (13.1%).
Business Highlights
- Operating revenue rose modestly year over year (Q2 +0.8%, YTD +1.2%), supported by premium rate increases and growth in CarelonRx.
- Total medical membership fell 1.5% year over year, driven by Medicaid attrition and lower Medicare Advantage enrollment.
- Expanded Public Exchange presence in Florida, Maryland, Texas and Washington and recorded growth in CarelonRx product revenues and specialty pharmacy.
- Elevated medical cost trends prompted targeted medical management efforts, regulatory actions and the launch of a 2026–2027 Transformation Program to address margins.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.